AustraliaHealth

Biome Australia (ASX:BIO) executed a two-year extension to its exclusive supply agreement with Probiotical.

Bioxyne (ASX:BXN) announced a major $50 million exclusive supply agreement with German pharmaceutical giant ADREXpharma.

EMVision Medical Devices (ASX:EMV) announced an expansion of its pivotal FDA De Novo trial.

BCAL Diagnostics (ASX:BDX), an Australian healthcare innovator specialising in early-stage cancer detection, appointed Anne-Louise Arnett as its CEO.

Biotech giant CSL (ASX:CSL) issued an update to its 2026 financial year outlook, softening revenue and profit expectations.

Amplia Therapeutics (ASX:ATX) has partnered with the Australia New Zealand Gynaecological Oncology Group to launch a new clinical trial targeting ovarian cancer.

Ramsay Santé booked a 3.1% revenue rise to €4bn in its 9M results, driven by strong Nordic performance and French demand.

PYC Therapeutics (ASX:PYC) announced the dosing of the first patient in the Phase 1b multiple ascending dose study of PYC-003.

Neuren Pharmaceuticals (ASX:NEU) reported net sales of its flagship Rett syndrome treatment, DAYBUE (trofinetide) in Q1.

Arovella Therapeutics (ASX:ALA) appointed Dr Nicole Van Der Weerden as acting CEO, effective immediately.

Anteris Technologies (ASX:AVR) treats first US patients in PARADIGM trial, marking a major milestone for its DurAVR heart valve.

Health technology firm Beamtree (ASX:BMT) announced a pivotal $2 million contract with Saudi Arabia’s Fakeeh Care Group.